Delcath announces publication supporting early use of liver-directed therapy

Delcath Systems (DCTH) announced the publication of results from a retrospective analysis conducted by researchers at the University of Tubingen, Germany. The study, published in the International Journal of Cancer, highlights the potential benefits of early use of liver-directed therapies, including chemosaturation, also known as percutaneous hepatic perfusion or PHP, in achieving long-term survival for patients with metastatic uveal melanoma. The analysis underscores PHP’s advantages in disease control compared to other therapies. The study utilized Delcath’s CHEMOSAT Hepatic Delivery System. The analysis of 167 patients found that the majority of long-term survivors received liver-directed therapy as their first-line treatment, and patients who received first-line liver-specific therapy had a disease control rate of 93% vs. 63% for those receiving first-line systemic therapy.